Compare ACDC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACDC | COLL |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.3M | 1.2B |
| IPO Year | 2021 | 2015 |
| Metric | ACDC | COLL |
|---|---|---|
| Price | $6.39 | $35.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $5.83 | ★ $51.17 |
| AVG Volume (30 Days) | ★ 1.4M | 461.1K |
| Earning Date | 03-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | ★ $1,941,800,000.00 | $780,567,000.00 |
| Revenue This Year | N/A | $5.93 |
| Revenue Next Year | $6.37 | N/A |
| P/E Ratio | ★ N/A | $21.08 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $3.08 | $23.23 |
| 52 Week High | $10.70 | $50.79 |
| Indicator | ACDC | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 31.36 |
| Support Level | $3.48 | $34.29 |
| Resistance Level | $7.47 | $36.20 |
| Average True Range (ATR) | 0.49 | 1.31 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 56.05 | 17.58 |
ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. The company operates in three segments: Stimulation Services, Proppant Production, and Manufacturing. Stimulation services, which generate the majority of the revenue for the company operate a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.